Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | INX-315 |
Synonyms | |
Therapy Description |
INX-315 inhibits CDK2, potentially leading to decreased Rb phosphorylation, cell cycle arrest, and reduced tumor cell proliferation and growth in CCNE1-amplified tumors (PMID: 38047585). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
INX-315 | INX315|INX 315 | CDK2 Inhibitor 31 | INX-315 inhibits CDK2, potentially leading to decreased Rb phosphorylation, cell cycle arrest, and reduced tumor cell proliferation and growth in CCNE1-amplified tumors (PMID: 38047585). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05735080 | Phase Ib/II | INX-315 | Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer (INX-315-01) | Recruiting | USA | AUS | 0 |